Glaxo (GSK) and XenoPort (XNPT) Announed that U.S. FDA Has Extended the Review Date of GSK1838262/XP13512
More News related to GSK
- Gilead Sciences (GILD) and Glaxo (GSK) Agree to Commercialize Viread Hep B Treatment in Five Asian Countries
- Gilead and GlaxoSmithKline Announce Agreement to Commercialize Viread(R) for Chronic Hepatitis B in Key Asian Countries
- Leerink Swann Initiates Coverage on GlaxoSmithKline (GSK) with a Market Perform
- Valent Pharma (VRX) Shares Ride the Lightning, But Is the Storm Breaking? - Barron's (GSK)
- Trading Review for Vivus Inc. Issued by Beacon Equity
More News related to XNPT
- XenoPort (XNPT) and Astellas Pharma Announce an Application for RLS Treatment XP13512 Filed with PMDA in Japan
- Astellas and XenoPort Announce Submission of a New Drug Application in Japan Requesting PMDA Approval of ASP8825/XP13512 for Restless Legs Syndrome
- CORRECTING and REPLACING GlaxoSmithKline and XenoPort Announce Extension of GSK1838262 (XP13512) FDA Review Date to February 9, 2010
- Glaxo (GSK) and XenoPort (XNPT) Announed that U.S. FDA Has Extended the Review Date of GSK1838262/XP13512
- GlaxoSmithKline and XenoPort Announce Extension of GSK1838262 (XP13512) FDA Review Date to February 9, 2010
More News related to Corporate News
- Wunderlich Securities Downgrades Gran Tierra Energy (GTE) to Hold
- Stephens Downgrades Benihana (BNHN) to Equalweight
- UBS Downgrades NRG Energy (NRG) to Neutral; Cuts Target to $26
- Citi Cuts Lukoil (LUKOY) to Hold
GlaxoSmithKline (NYSE: GSK) and XenoPort, Inc. (NASDAQ: XNPT) today announced that the U.S. Food and Drug Administration (FDA) has extended the original Prescription Drug User Fee Act (PDUFA) goal date for its review of the New Drug Application (NDA) for GSK1838262/XP13512 (gabapentin enacarbil) to February 9, 2010. The original PDUFA date for this NDA review was November 9, 2009.
The FDA determined that a Risk Evaluation and Mitigation Strategy (REMS) was necessary for GSK1838262. In response to FDA's request, GSK submitted a proposed REMS. The FDA accepted this submission as a solicited major amendment to the GSK1838262 NDA. The FDA has the option to extend the PDUFA goal date when a sponsor submits a major amendment that provides a substantial amount of new data not previously reviewed by the FDA.
Related Categories
Corporate NewsFDA
Stocks Mentioned
+0.60Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
